Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $2.44 on Friday. The firm has a market capitalization of $98.36 million, a P/E ratio of 22.18 and a beta of 1.70. The stock has a 50 day moving average price of $2.38 and a 200-day moving average price of $2.41. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67.

Institutional Trading of Oramed Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ORMP. XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals during the second quarter valued at $40,000. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Oramed Pharmaceuticals in the 3rd quarter worth about $272,000. Renaissance Technologies LLC grew its position in Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares during the last quarter. Finally, Murchinson Ltd. grew its position in Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares during the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.